Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis Recruitment of 232 patients completed ahead of schedule with minimal impact by the Covid-19 pandemic Top-line results expected to be available in Q2 2021 Maintenance open label extension Phase 2b study in UC progressing well with 130 patients enrolled and expan [ … ]

Abivax Receives "Best Technology Award" at the European Mediscience Awards 2020 Recognizes innovative and unique mechanism of action of ABX464, with its antiviral, anti-inflammatory and tissue repair characteristics In Phase 2b trial in ulcerative colitis, Phase 2a in rheumatoid arthritis, Phase 2b/3 in high-risk Covid-19 patients; pivotal Phase  [ … ]

Abivax announces webcast and teleconference following recent oversubscribed capital increase of  EUR 28m at market price PARIS, November 02, 2020 - 2:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases [ … ]

Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.) Total financing since June 2020 amounting to EUR 84m, 2/3 non-dilutive (EUR 56m from Bpifrance, Kreos, Soc [ … ]

Abivax secures EUR 15m non-dilutive financing from Kreos Capital EUR 15m straight bonds, with no associated dilution, favorable financial conditions in interest rates and no expected transaction fees Pre-negotiated EUR 5m additional straight bond tranche to be decided before 2020 year-end Cash for operations extended until Q2 2021 PARIS, October [ … ]

Abivax announces the release of its 2020 half-year financial report PARIS, France, September 30, 2020 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the publicati [ … ]

Abivax presents first-half 2020 financial results and operations update ABX464 Phase 2a ulcerative colitis two-year maintenance study results confirm good safety profile and durable efficacy of 50 mg once-daily oral ABX464 77% (180/232) of patients randomized in ABX464 Phase 2b ulcerative colitis study, recruitment expected to be completed by the [ … ]

Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study Phase 2a open label maintenance results after second year of treatment confirm good safety profile and durable efficacy of 50mg once-daily oral ABX464 After the second year of continued treatment, 69% of patients were in clinic [ … ]